Gilead Sciences Inc (GILD)
Gilead - U.S. FDA ApprovesGilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Gilead - U.S. FDA ApprovesGilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Riassunto: Kioxia e Sandisk investiranno oltre 31 miliardi di dollari in Giappone, estendendo la leadership nel settore della memoria
FTK Investors Have Opportunity to Lead Flotek Industries, Inc. Securities Fraud Lawsuit with SBS Law